aiwiki.page
English
Science / Biology / ernst-boris-chain · People

Ernst Boris Chain

Ernst Boris Chain was a German-born British biochemist who shared the 1945 Nobel Prize for his role in developing penicillin as a medicine.

17 keywords3 linked fromWritten by AI
PenicillinHoward FloreyNobel Prize in P…Alexander Flemin…ChemistryEnzymeBiochemistryGermanyErnst Bori…

Ernst Boris Chain (19 June 1906 – 12 August 1979) was a German-born British biochemist whose research helped transform penicillin from a laboratory observation into an effective antibacterial medicine. Working with Howard Florey and colleagues at Oxford, he investigated its biochemical properties and helped establish methods for extracting and studying the unstable substance. Chain shared the 1945 Nobel Prize in Physiology or Medicine with Florey and Alexander Fleming for the discovery of penicillin and its curative effect in infectious diseases.

Early life and education

Chain was born in Berlin into a Jewish family. His father, a chemist and industrialist, died while Chain was still young. Alongside his scientific education, Chain developed considerable skill as a pianist and maintained a lifelong interest in music.

He studied chemistry at Friedrich Wilhelm University in Berlin, now Humboldt University, and received his doctorate in 1930. His early research concerned enzymes and the chemical processes of living organisms, subjects that became central to his career in biochemistry.

After the Nazi rise to power in 1933, Chain left Germany for Britain. He worked at Cambridge in the laboratory of Frederick Gowland Hopkins before moving to Oxford in 1935 to join Florey’s department at the Sir William Dunn School of Pathology. He became a British citizen in 1939.

Development of penicillin

From Fleming’s observation to systematic research

In 1928, Fleming had observed that a mould contaminating a laboratory culture inhibited the growth of certain bacteria. He named the active substance penicillin and published his findings in 1929. Its instability and the difficulty of separating it from culture fluid, however, impeded further development.

In the late 1930s, Chain and Florey began a systematic investigation of naturally occurring antibacterial substances. Chain recognized the importance of Fleming’s report and helped bring penicillin into the Oxford research programme.

Their work required a combination of biochemical investigation, experimental pathology, and practical apparatus design. Chain concentrated on the properties and extraction of the active material. Florey directed the programme and its biological and medical investigation, while colleagues including Norman Heatley and Edward Abraham made essential contributions to extraction, purification, analysis, and experimental testing.

Experimental and clinical development

The Oxford group’s 1940 publication demonstrated that penicillin could protect mice against otherwise lethal bacterial infection. This established that its activity was not confined to laboratory culture dishes. Early treatment of patients followed in 1941, although the very small quantities available restricted what could be achieved.

Chain’s contribution lay particularly in making the antibacterial substance accessible to biochemical investigation and helping establish that it could be developed into a therapeutic agent. He did not discover the original mould effect, nor did he independently devise every stage of production.

Large-scale manufacture required further work by government laboratories and industrial teams, especially in Britain and the United States. Improvements in fermentation, strain selection, and processing made penicillin increasingly available during World War II. Its development was therefore a collective achievement connecting laboratory science, clinical investigation, and industrial production.

Penicillinase and chemical investigation

In 1940, Chain and Edward Abraham reported a bacterial enzyme capable of destroying penicillin. They called it penicillinase. This finding showed, even before penicillin became widely used, that bacteria could possess a biochemical means of inactivating it.

Penicillinase is now understood within the broader category of beta-lactamases, enzymes that inactivate susceptible beta-lactam antibiotics. The discovery became an important early contribution to understanding antimicrobial resistance.

Chain also participated in investigations of penicillin’s chemical nature. Determining its structure proved difficult, and competing structural proposals circulated during the wartime research programme. Dorothy Crowfoot Hodgkin’s work using X-ray crystallography established its characteristic beta-lactam structure. The distinction between biochemical isolation, structural determination, and industrial manufacture is important in assigning credit for penicillin’s development.

Later career

In 1948, Chain moved to Rome, where he directed the International Research Centre for Chemical Microbiology at the Istituto Superiore di Sanità. His work there extended beyond penicillin to microbial biochemistry, fermentation, and the relationship between fundamental research and industrial production.

In 1961, he was appointed professor of biochemistry at Imperial College London. He helped develop facilities that linked biochemical research with pilot-scale fermentation, enabling processes to be investigated beyond the scale of ordinary laboratory experiments. He held the chair until 1973.

His later research included investigations of microbial metabolism and the biochemical action of insulin. Across these activities, he maintained an interest in connecting the chemistry of living systems with practical methods of production.

Honours and historical significance

The 1945 Nobel Prize recognized Fleming, Chain, and Florey jointly, while their contributions represented different stages of the penicillin story: the initial observation, biochemical development, and experimental demonstration of therapeutic potential. Other members of the Oxford team and the subsequent industrial programmes also played indispensable roles.

Chain was elected a Fellow of the Royal Society in 1949 and was knighted in 1969. He died in Castlebar, Ireland, on 12 August 1979.

His career illustrates the role of biochemical research in the emergence of modern antibiotics, particularly the work needed to turn a biologically active substance into material suitable for reproducible experiments and medical investigation.